Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been assigned a consensus rating of “Moderate Buy” from the twelve research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $39.4444.

A number of research firms have recently issued reports on AGIO. Leerink Partnrs upgraded Agios Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 20th. Zacks Research raised shares of Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 4th. The Goldman Sachs Group lowered their price objective on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating on the stock in a research note on Thursday, November 20th. Royal Bank Of Canada cut shares of Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and reduced their target price for the company from $57.00 to $28.00 in a report on Wednesday, November 19th. Finally, Truist Financial increased their price target on shares of Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, December 24th.

Insider Transactions at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,932 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total transaction of $79,427.88. Following the transaction, the insider directly owned 29,190 shares of the company’s stock, valued at $790,757.10. The trade was a 9.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider James William Burns sold 2,932 shares of the firm’s stock in a transaction that occurred on Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total transaction of $79,427.88. Following the sale, the insider owned 31,718 shares in the company, valued at approximately $859,240.62. The trade was a 8.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 37,005 shares of company stock valued at $1,064,531. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. NewEdge Advisors LLC acquired a new position in Agios Pharmaceuticals during the first quarter worth approximately $40,000. First Horizon Corp purchased a new position in shares of Agios Pharmaceuticals during the third quarter worth approximately $45,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Agios Pharmaceuticals by 16.7% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 320 shares during the period. Quantbot Technologies LP acquired a new position in shares of Agios Pharmaceuticals in the 3rd quarter valued at $79,000. Finally, Acadian Asset Management LLC purchased a new stake in Agios Pharmaceuticals in the 1st quarter valued at $133,000.

Agios Pharmaceuticals Trading Up 3.3%

Agios Pharmaceuticals stock opened at $28.73 on Thursday. Agios Pharmaceuticals has a 12 month low of $22.24 and a 12 month high of $46.00. The company has a market capitalization of $1.68 billion, a price-to-earnings ratio of -4.10 and a beta of 0.89. The business’s fifty day simple moving average is $29.99 and its two-hundred day simple moving average is $35.64.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, topping the consensus estimate of ($1.93) by $0.15. The firm had revenue of $12.88 million during the quarter, compared to analysts’ expectations of $10.49 million. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The company’s revenue was up 43.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $16.22 earnings per share. On average, equities research analysts predict that Agios Pharmaceuticals will post -6.85 EPS for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.